Odysight.Ai Inc. (ODYS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Odysight.Ai Inc. is a pioneer in vision-based platform solutions for Predictive Maintenance (PdM) and Condition Based Monitoring (CBM), utilizing AI and machine learning to monitor critical safety components in hard-to-reach locations. The company operates primarily in the aerospace, defense, medical, and Industry 4.0 sectors. As of November 12, 2025, the company had approximately 16.36 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $149,000 | $1,292,000 | $2,576,000 | $2,660,000 |
| Gross Profit | $23,000 | $405,000 | $694,000 | $696,000 |
| Operating Loss | $(4,707,000) | $(3,016,000) | $(13,705,000) | $(8,744,000) |
| Net Loss | $(4,416,000) | $(2,867,000) | $(12,756,000) | $(8,211,000) |
| Cash & Equivalents | $29.5 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $(58.7) million (as of Sept 30, 2025) | |||
| Backlog | $14.2 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Q3 2025 revenue dropped 88% year-over-year to $149,000. This is primarily due to the derecognition of a contract liability and fulfillment asset associated with a Fortune 500 medical customer in Q1 2025, as no purchase order was received for 2025.
- Expense Growth: Operating expenses increased significantly. Research and Development (R&D) expenses rose 43% in Q3 and 56% YTD, driven by new product development and hiring. Sales and Marketing expenses increased 67% in Q3 and 99% YTD due to market expansion efforts. General and Administrative (G&A) expenses rose 24% in Q3 and 39% YTD, attributed to new executive hires (including a CFO) and costs related to the Nasdaq uplisting.
- Liquidity Improvement: Cash and cash equivalents increased from $18.2 million at year-end 2024 to $29.5 million at Q3 2025, bolstered by a public offering in February 2025 that generated net proceeds of approximately $20.9 million.
- Inventory: Inventory was fully written down to zero in Q1 2025 due to the cancellation of the medical customer project, resulting in a $203,000 impairment charge.
Guidance, Outlook, and Risks
- Outlook: Management expects expenses to continue growing as the company scales R&D and commercialization efforts in the Industry 4.0 domain. The company believes current cash resources will fund operations for at least the next 12 months but anticipates a need for additional capital to achieve profitability.
- War in Israel: The company notes that while the ongoing conflict has caused minor operational disruptions (e.g., sheltering employees, reserve duty for executives), it has not had a material adverse effect on business to date. Conversely, increased flight hours by the Israeli Air Force have generated growing interest in the company's technology from government clients.
- Risks: Key risks include dependence on a limited number of customers, the need for additional financing, potential delays in purchase orders due to geopolitical instability, and the ability to scale operations and protect intellectual property.
- Unusual Items: The derecognition of $1.7 million in contract liabilities and $957,000 in fulfillment assets related to the medical customer in Q1 2025 significantly impacted the financial trajectory for the year.
Investor Verification Checklist
- Verify the status of the $14.2 million backlog and the likelihood of conversion to revenue given the loss of the major medical customer.
- Monitor the burn rate relative to the $29.5 million cash balance to assess the runway before the next potential capital raise.
- Review the specific progress of Industry 4.0 and defense contracts to determine if they can offset the loss of medical sector revenue.
- Assess the impact of the war in Israel on supply chains and the ability to execute on international contracts.
- Confirm the timeline for profitability given the aggressive increase in R&D and G&A spending.